17:07 EST NewAmsterdam Pharma (NAMS) files $500M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress
- NewAmsterdam Pharma price target raised to $52 from $47 at Scotiabank
- Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence
- Promising Outlook for NewAmsterdam Pharma: Buy Rating Affirmed Amid Successful Trials and Strong Financial Position
- Promising Drug Developments and Positive Trial Results Drive Buy Rating for NewAmsterdam Pharma